CICarsten Walter Israel

Carsten Walter Israel

*This is an algorithmically generated author record based on publicly available information.

Carsten Walter Israel has a total of 135 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Volume–outcome analysis of in-hospital complications after cardiac implantable electronic device implantation: a 250 000-case study

    by Paulina Vitkauskė, Maurilio Gutzeit, Heike Jaegers, Heinz-Jürgen Adomeit, Susanne Macher-Heidrich, Fuad Hasan, Markus Zarse, Harilaos Bogossian, Uwe Wiegand, Axel Kloppe, et al.

    Aims: Although implantation volume of cardiac implantable electronic device (CIED) is widely considered a prognostic factor, Germany continues to show a wide distribution of hospitals performing CIED procedures, with annual volumes ranging from fewer than 10 to over 500 cases. Using a new statistical volume–outcome model, we examined the existence and shape of the relationship between complication rates and hospital volume. Methods and results: The analysis is based on data from all first inpatient CIED implantations performed between 1 January 2010 and 31 December 2020, in hospitals across North Rhine-Westphalia. All peri- and post-operative complications documented in mandatory quality assurance were included. A possible association between implantation volume and quality was assessed using a flexible generalized additive mixed model. Out of 249 118 cases, the overall complication rate was 2.4%, with lead-related issues being the most common (1.5%). Forest plot analysis identified American Society of Anaesthesiologists Class 4–5, New York Heart Association Class IV, subclavian vein access, and dual-chamber pacemaker systems as the strongest predictors of complications. Volume–outcome analysis revealed a significant association between implantation volume and complications, particularly among pacemaker patients [P < 0.001, area under the curve (AUC) 0.7], and showed a relevant reduction in hospital stays and healthcare costs. Modelling suggested that a 50-case annual cut-off could prevent ∼16% of complications, requiring ∼16% of patients to be redirected to other hospitals. Conclusion: This study demonstrates a statistically significant association between implantation volume and complication rates across all CIED procedures, with the effect being particularly pronounced among pacemaker patients.


  • Open Access

    Cardiac implantable electronic device upgrades and downgrades: a Clinical Consensus Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Asia Pacific Heart Rhythm Association (APHRS), Canadian Heart Rhythm Society (CHRS), Heart Rhythm Society (HRS), and the Latin American Heart Rhythm Society (LAHRS)

    by Daniel Keene, Jens Cosedis Nielsen, Haran Burri, Carlos Alejandro Chavez-Gutierrez, Jean-Claude Deharo, Inga Drossart, James E Ip, Carsten W Israel, Jens Brock Johansen, Annamaria Kosztin, et al.

    Cardiac implantable electronic device upgrade and downgrade procedures are increasingly being performed. Whilst the most appropriate guideline-recommended device may have been followed during a patient's initial procedure, the requirements of patients can change over time. This could be due to worsening of cardiac function due to detrimental effects of pacing itself or the diagnosis, development, or progression of another cardiac comorbidity. Device downgrades are also performed when a patient's clinical state changes and are often considered in patients with increased frailty and comorbidity. This clinical consensus statement aims to provide a framework for screening patients for device upgrade, pre-procedural planning considerations, available procedural strategies, namely a summary of techniques and approaches for vascular access, including ipsilateral and contralateral options, and a framework for when extraction to gain access may be appropriate. The document also provides advice on how to frame an ethical discussion with patients and carers on available options.


  • Open Access

    A review on wearable cardioverter-defibrillators in clinical practice for sudden cardiac death prevention and heart failure management

    by David Duncker, Rodrigue Garcia, Diana Bonderman, Giancarlo Casolo, Michał Farkowski, Carsten Israel, Eloi Marijon

    Sudden cardiac death (SCD) remains a predominant mode of death in cardiovascular mortality. Despite advancements in guideline-recommended medical therapy and risk stratification, accurately identifying patients who would benefit most from implantable cardioverter-defibrillator (ICD) therapy over the long term remains a significant challenge. The wearable cardioverter-defibrillator (WCD) has emerged as a non-invasive bridge to either ICD implantation or recovery of left ventricular function. This expert review presents a comprehensive and up-to-date summary of clinical evidence on WCD use for SCD prevention and heart failure (HF) management. Specifically, it will address: (i) the concept and mechanism of the WCD; (ii) evidence from randomized and observational studies regarding efficacy, safety, and cost-effectiveness; (iii) integration of the WCD into HF management; and (iv) knowledge gaps and priorities for future research.


  • Top Cited Papers
    Open Access

    European Society of Cardiology (ESC) clinical consensus statement on indications for conduction system pacing, with special contribution of the European Heart Rhythm Association of the ESC and endorsed by the Asia Pacific Heart Rhythm Society, the Canadian Heart Rhythm Society, the Heart Rhythm Society, and the Latin American Heart Rhythm Society

    by Michael Glikson, Haran Burri, Amr Abdin, Oscar Cano, Karol Curila, Jan De Pooter, Juan C Diaz, Inga Drossart, Weijian Huang, Carsten W Israel, et al.

    Conduction system pacing (CSP) is being increasingly adopted as a more physiological alternative to right ventricular and biventricular pacing. Since the 2021 European Society of Cardiology pacing guidelines, there has been growing evidence that this therapy is safe and effective. Furthermore, left bundle branch area pacing was not covered in these guidelines due to limited evidence at that time. This Clinical Consensus Statement provides advice on indications for CSP, taking into account the significant evolution in this domain.


  • World Stroke Organization Brain & hEart globAl iniTiative Program

    by Luciano A. Sposato, Sheila Martins, Jan F. Scheitz, Sara Aspberg, M Edip Gurol, Mohamed Abdalla, Antonio Arauz, Vanessa Cano-Nigenda, Paul Fiorilli, Carsten Israel, et al.

    Introduction: The World Stroke Organization (WSO) Brain & Heart Task Force developed the Brain & hEart globAl iniTiative (BEAT), a pilot feasibility implementation program to establish clinical collaborations between cardiologists and stroke physicians who work at large healthcare facilities. Methods: The WSO BEAT pilot project focused on atrial fibrillation (AF) and patent foramen ovale (PFO) detection and management, and poststroke cardiovascular complications known as the stroke-heart syndrome. The program included 10 sites from 8 countries: Brazil, China, Egypt, Germany, Japan, Mexico, Romania, and the USA The primary composite feasibility outcome was the achievement of the following 3 implementation metrics (1) developing site-specific clinical pathways for the diagnosis and management of AF, PFO, and the stroke-heart syndrome; (2) establishing regular Neurocardiology rounds (e.g., monthly); and (3) incorporating a cardiologist to the stroke team. The secondary objectives were (1) to identify implementation challenges to guide a larger program and (2) to describe qualitative improvements. Results: The WSO BEAT pilot feasibility program achieved the prespecified primary composite outcome in 9 of 10 (90%) sites. The most common challenges were the limited access to specific medications (e.g., direct oral anticoagulants) and diagnostic (e.g., prolonged cardiac monitoring) or therapeutic (e.g., PFO closure devices) technologies. The most relevant qualitative improvement was the achievement of a more homogeneous diagnostic and therapeutic approach. Conclusion: The WSO BEAT pilot program suggests that developing neurocardiology collaborations is feasible. The long-term sustainability of the WSO BEAT program and its impact on quality of stroke care and clinical outcomes needs to be tested in a larger and longer duration program.


  • Änderung der Indikation zur primärprophylaktischen ICD-Implantation

    by Felix Wiedmann, Carsten W. Israel, Constanze Schmidt

    Die Versorgung mit einem implantierbaren Kardioverter-Defibrillator (ICD) bietet einen effektiven Schutz vor lebensgefährlichen Herzrhythmusstörungen. Da es sich beim plötzlichen Herztod um ein unvorhersehbares Ereignis handelt, stellt die Selektion des Patientenguts, das von einer ICD-Implantation profitiert, jedoch nach wie vor eine große Herausforderung dar. Die Evidenz, auf der die aktuellen Leitlinienempfehlungen zur ICD-Implantation aufbauen, begründet sich zu einem relevanten Teil auf Studien, die bereits vor 20–30 Jahren durchgeführt wurden. Seitdem hat sich die medikamentöse und interventionelle Herzinsuffizienztherapie deutlich weiterentwickelt. Zudem stellen neuere Studien den prognostischen Nutzen einer primärprophylaktischen ICD-Implantation bei Patienten mit nicht ischämischer Kardiomyopathie infrage. Im Folgenden soll anhand der zugrunde liegenden Daten erörtert werden, welche Implikationen sich hieraus für den Alltag ergeben und welche Entwicklungen zukünftig zu erwarten sind. The use of implantable cardioverter defibrillators (ICD) provides effective protection against life-threatening cardiac arrhythmias. As sudden cardiac death is an unpredictable event, however, selection of the patient population that will benefit from ICD implantation remains a major challenge. The evidence on which the current guideline recommendations for ICD implantation are based is to a relevant extent based on studies that recruited patients 20–30 years ago, a period in which drug and interventional heart failure therapy has evolved significantly. In addition, more recent studies question the prognostic benefit of primary prophylactic ICD implantation in patients with nonischemic cardiomyopathy. In the following, based on the underlying data, we will discuss the implications for everyday practice and what developments can be expected in the near future. Article published online: 08 August 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke

    by William F McIntyre, Jia Wang, Alexander P Benz, Linda Johnson, Stuart J Connolly, Isabelle C Van Gelder, Renato D Lopes, Michael R Gold, Stefan H Hohnloser, Chu Pak Lau, et al.

    There is uncertainty about whether and how to perform screening for atrial fibrillation (AF). To estimate the incidence of previously undetected AF that would be captured using a continuous 14-day ECG monitor and the associated risk of stroke. We analysed data from a cohort of patients >65 years old with hypertension and a pacemaker, but without known AF. For each participant, we simulated 1000 ECG monitors by randomly selecting 14-day windows in the 6 months following enrolment and calculated the average AF burden (total time in AF). We used Cox proportional hazards models adjusted for CHA2DS2-VASc score to estimate the risk of subsequent ischaemic stroke or systemic embolism (SSE) associated with burdens of AF > and 2DS2-VASc score was 4.0, and 44 patients experienced SSE after 6 months following enrolment. The proportion of participants with an AF burden >6 min was 3.10% (95% CI 2.53–3.72). This was consistent across strata of age and CHA2DS2-VASc scores. Over a mean follow-up of 2.4 years, the rate of SSE among patients with 6 min of AF. Approximately 3% of individuals aged >65 years with hypertension may have more than 6 min of AF detected by a 14-day ECG monitor. This is associated with a stroke risk of over 2% per year. Whether oral anticoagulation will reduce stroke in these patients is unknown.


  • Detection of Atrial Fibrillation on Stroke Units: Comparison of Manual versus Automatic Analysis of Continuous Telemetry

    by Andreas Rogalewski, Jorge Plümer, Tobias Feldmann, Christian Oelschläger, Isabell Greeve, Alkisti Kitsiou, Peter D. Schellinger, Carsten Walter Israel, Wolf-Rüdiger Schäbitz

    Background: Detection of atrial fibrillation (AF) is one of the primary diagnostic goals for patients on a stroke unit. Physician-based manual analysis of continuous ECG monitoring is regarded as the gold standard for AF detection but requires considerable resources. Recently, automated computer-based analysis of RR intervals was established to simplify AF detection. The present prospective study analyzes both methods head to head regarding AF detection specificity, sensitivity, and overall effectiveness. Methods: Consecutive stroke patients without history of AF or proof of AF in the admission ECG were enrolled over the period of 7 months. All patients received continuous ECG telemetry during the complete stay on the stroke unit. All ECGs underwent automated analysis by a commercially available program. Blinded to these results, all ECG tracings were also assessed manually. Sensitivity, specificity, time consumption, costs per day, and cost-effectiveness were compared. Results: 216 consecutive patients were enrolled (70.7 ± 14.1 years, 56% male) and 555 analysis days compared. AF was detected by manual ECG analysis on 37 days (6.7%) and automatically on 57 days (10.3%). Specificity of the automated algorithm was 94.6% and sensitivity 78.4% (28 [5.0%] false positive and 8 [1.4%] false negative). Patients with AF were older and had more often arterial hypertension, higher NIHSS at admission, more often left atrial dilatation, and a higher CHA2DS2-VASc score. Automation significantly reduced human resources but was more expensive compared to manual analysis alone. Conclusion: Automatic AF detection is highly specific, but sensitivity is relatively low. Results of this study suggest that automated computer-based AF detection should be rather complementary to manual ECG analysis than replacing it.


  • Kardiale elektrische Device-Therapie bei Herzinsuffizienz

    by Carsten W. Israel, Sona Tribunyan

    Eine chronische Herzinsuffizienz stellt die Endstrecke von Erkrankungen mit kardialer Beteiligung dar und limitiert Prognose sowie Lebensqualität des Patienten. Therapeutisch kann der Verlauf durch kardiale implantierbare elektrische Devices (CIEDs) günstig beeinflusst werden. Die differenzierten Einsatzmöglichkeiten von CIEDs werden im Folgenden dargestellt. Heart failure is one of the most common reasons for inpatient treatment and one of the most common causes of death in Germany. In addition to coronary heart disease (ischemic cardiomyopathy, ICM), there are also numerous other diseases as non-ischemic cardiomyopathy, NICM. Chronic heart failure is the final stage of diseases with cardiac involvement and limits the prognosis and quality of life of patients. The course can be favorably influenced by cardiac implantable electrical devices (CIEDs). There are different uses of CIEDs which are shown in this article. Publication Date: 24 September 2020 (online) © Georg Thieme Verlag KG Stuttgart · New York